This site is for U.S. Healthcare Professionals only.
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
Oral
T-DXd
ESMO 2024 | September 13-17, 2024
HER2-low and HER2-ultralow status determination in tumors of patients with hormone receptor–positive metastatic breast cancer in DESTINY-Breast06
Poster
HER3-DXd
ESMO 2024 | September 13-17, 2024
HERTHENA-PanTumor01: A global, phase 2 trial of HER3-DXd in metastatic solid tumors
Poster
I-DXd
ESMO 2024 | September 13-17, 2024
IDeate-Lung03: A phase 1b/2 study of ifinatamab deruxtecan (I-DXd) plus atezolizumab with or without carboplatin as first-line induction or maintenance in patients with extensive-stage small cell lung cancer
Poster
I-DXd
ESMO 2024 | September 13-17, 2024
Intracranial response in patients with baseline brain metastases and extensive-stage small cell lung cancer treated with ifinatamab deruxtecan (I-DXd) in the IDeate-Lung01 study
Oral
T-DXd
ESMO 2024 | September 13-17, 2024
Phase II study of trastuzumab deruxtecan in patients with HER2-positive recurrent or metastatic salivary gland cancer: Results from the MYTHOS trial
Oral
DS-9606
ESMO 2024 | September 13-17, 2024
Preliminary results from a phase 1, first-in-human study of DS-9606, a Claudin 6 (CLDN6)-directed antibody–drug conjugate, in patients with tumor types known to express CLDN6
Oral
T-DXd
ESMO 2024 | September 13-17, 2024
Trastuzumab deruxtecan in patients with HER2+ advanced/metastatic breast cancer with or without brain metastases: DESTINY-Breast12 primary results
Oral
T-DXd
ESMO 2024 | September 13-17, 2024
Trastuzumab deruxtecan monotherapy and combinations in patients with advanced/metastatic HER2-positive esophageal, gastric or gastroesophageal junction adenocarcinoma: DESTINY-Gastric03 (DG-03)
Poster
T-DXd
ESMO 2024 | September 13-17, 2024
Treatment patterns and outcomes in HER2-low, HR+ metastatic breast cancer patients previously treated with endocrine therapy in the United States
Pages:
1 2